A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Non-small Cell Lung Cancer (NSCLC)|Triple Negative Breast Cancer (TNBC)|Pancreatic Ductal Adenocarcinoma (PDAC)|Colorectal Cancer Microsatellite Stable (MSS)|Ovarian Cancer|Renal Cell Carcinoma (RCC)|Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions: OTHER: NZV930|OTHER: PDR001|DRUG: NIR178
Sponsor: Novartis Pharmaceuticals